---
title: "Mentari Therapeutics falls 19% on reverse split and name change"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305028346.md"
description: "Mentari Therapeutics fell 18.56% to $13.03 after completing a 1-for-10 reverse split and renaming from InMed Pharmaceuticals."
datetime: "2026-11-10T17:58:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305028346.md)
  - [en](https://longbridge.com/en/news/305028346.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305028346.md)
generator: "portal-rs"
---

# Mentari Therapeutics falls 19% on reverse split and name change

Mentari Therapeutics (MTRI.US) fell nearly **19%** during regular trading to **$13.03**.

The company completed a 1-for-10 reverse stock split on Nov. 4, 2026, reducing outstanding shares to approximately **549,374** from about **5.49 million**, and changed its name from InMed Pharmaceuticals to Mentari Therapeutics.

The company outlined development plans for its migraine drug pipeline. It intends to file a regulatory application for candidate MT-002 in the first quarter of 2027 and expects to release Phase 1 clinical data by year-end.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30](https://longbridge.com/en/news/305028486.md)
- [Mentari Therapeutics Presents Migraine Drug Pipeline, Targets First Clinical Data in 2027](https://longbridge.com/en/news/304878301.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**